SNDX - Syndax Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.09
0.00 (0.00%)
At close: 4:00PM EDT

9.09 0.00 (0.00%)
After hours: 4:25PM EDT

Stock chart is not supported by your current browser
Previous Close9.09
Open9.12
Bid9.09 x 800
Ask9.30 x 800
Day's Range9.01 - 9.22
52 Week Range3.39 - 9.66
Volume52,595
Avg. Volume156,187
Market Cap246.301M
Beta (3Y Monthly)2.35
PE Ratio (TTM)N/A
EPS (TTM)-2.65
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.75
Trade prices are not sourced from all markets
  • A Trio of Small Biotech Companies Garnering Attention
    TheStreet.com10 days ago

    A Trio of Small Biotech Companies Garnering Attention

    The three either have made recent progress toward advancing products in their pipelines or have caught the eye of analysts.

  • PR Newswire12 days ago

    Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias

    -- SNDX-5613 is a potent, highly selective, oral inhibitor of the interaction of Menin with the Mixed Lineage Leukemia (MLL) protein -- -- Strong tumor growth inhibition and improved survival observed ...

  • PR Newswirelast month

    Syndax to Present at the JMP Securities Life Sciences Conference

    WALTHAM, Mass. , June 13, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of SNDX earnings conference call or presentation 6-May-19 8:30pm GMT

    Q1 2019 Syndax Pharmaceuticals Inc Earnings Call

  • 5 Stellar Stocks For Under $10
    TipRanks2 months ago

    5 Stellar Stocks For Under $10

    You don’t have to pay three-digit sums to find compelling investing opportunities. It’s time to look outside the box at some cheap stocks top analysts are cheering right now. The best way to find these stocks is to use a screener, that way you can open up your investing horizon to a much wider stock pool.Here we used TipRanks’ Stock Screener to find these 5 cheap stocks. Essentially, we looked for 1) stocks with a ‘Strong Buy’ analyst consensus; 2) serious upside potential (i.e. over 20%). And on top of this each one of these stocks comes in at under $10. Note that the consensus is based on ratings from the last three months, so the outlook is pretty up to date. Plus we include top analyst analysis to show just why analysts believe these stocks are so undervalued right now.Let’s take a closer look: Syndax Pharmaceuticals Inc (SNDX – Research Report) Syndax Pharmaceuticals, Inc is a clinical-stage biopharma developing therapies for the treatment of cancer.The company offers significant rewards- but only for investors prepared to shoulder a hefty dose of risk. Shares could surge if the company’s Phase 3 trial of entinostat in metastatic breast cancer is positive. Indeed, Citigroup’s Joel Beatty says that such a catalyst could take shares all the way from $8 to $23. That suggests massive upside potential of 187%. However, the analyst also warns that should the data disappoint, shares could plunge to just $2 (75% downside potential). Look for the data to come in fall 2019 or spring 2020, says Beatty. In the meantime the analyst keeps a buy rating on shares. Encouragingly, the stock also scores a Strong Buy consensus from the Street. “Entinostat has received Breakthrough Therapy Designation in HR+ HER2- breast cancer patients, and we continue to believe that a positive OS assessment in E2112 could occur this year with a launch in 2021” writes HC Wainwright analyst Edward White. This five-star analyst has a $16 price target on shares (100% upside potential). That's just below the $19 average analyst price target. See what other Top Analysts are saying about SNDX. Turtle Beach Corp (HEAR – Research Report) Turtle Beach Corp is one of the leading gaming headset and audio accessory brand. Disappointing 2Q revenue guidance has weighed on shares recently, but it’s not game over for HEAR just yet.All five analysts covering the stock rate HEAR a ‘Buy.’ That’s with an average analyst price target of $23- indicating 150% upside potential from current levels. The best-rated analyst covering the stock is Oppenheimer’s Andrew Uerkwitz.He maintained his buy rating and $24 price target post-results. In a report on May 9 the analyst explained “With healthy fundamentals in video game market and integration of PC gaming accessories business (ROCCAT) well on track, we remain confident in management's ability to stay competitive and return to revenue growth in 2020.”As for the earnings report, the analyst explains that 2Q revenue guidance is lighter than expected, mostly due to order timing volatility in between quarters. However HEAR did reiterate 2019 revenues of $240-248M. “Over a two year basis, we believe Turtle Beach is outgrowing the competition and keeping its leading market share” he concludes. See what other Top Analysts are saying about HEAR. Pareteum Corp (TEUM – Research Report) Pareteum is a rapidly growing global cloud software communications platform. The company offers everything from voicemail and messaging services to data analytics and service fulfilment. Shares have exploded by 150% year-to-date following first-rate Q1 earnings results, and according to the analyst community plenty of upside lies ahead. This ‘Strong Buy’ stock scores 5 recent buy ratings, alongside an $8 average analyst price target (86% upside potential).Pareteum just hosted its first analyst day on May 28 in NYC. “We view this event as another sign of the further and rapid maturation of the company” cheers five-star Northland Securities analyst Michael Latimore. He has an $8.50 price target on shares. According to Latimore, Pareteum has a unique opportunity to be the cloud-based business and operations support system for agile mobile service providers. “TEUM is a top 2019 stock pick…. TEUM remains inexpensive still at only about 4x FY20 revenue v. comps at 10x” writes the analyst. See what other Top Analysts are saying about TEUM. Plug Power Inc (PLUG – Research Report) Plug Power develops cutting-edge fuel cells and hydrogen technologies that are more efficient than conventional batteries. Like Paretuem, PLUG has experienced a remarkable rally, with shares doubling year-to-date.Shares continued to move higher on May 29 following the announcement of an exciting new deal. Plug Power will now deliver hydrogen fuel cell engines to StreeScooter’s electric delivery vehicles. This ties into StreetScooter’s deal to initially deliver 100 hydrogen fuel cell-powered trucks for on-road use to Deutsche Post DHL starting in 2020. According to Plug Power this will provide increased drive time without the need for long charge hours.“We continue to be bullish on PLUG’s technology leadership position in mobile fuel cell applications and are encouraged by commentary about its expanding opportunity set in material handling and over-the-road applications” writes top-rated Oppenheimer analyst Colin Rusch. Four analysts have published buy ratings on PLUG in the last three months. Their average price target of $3.56 translates into upside potential of 37%. See what other Top Analysts are saying about PLUG. ViewRay, Inc. (VRAY – Research Report) Medical device company ViewRay is on a roll right now. The company just reported strong earnings results, and shares are up 47% year-to-date. Sean Lavin of BTIG praised the company’s current investment strategy, noting strong sales and steady sales progress. Indeed, gross orders came in an impressive $12 million above consensus. “This is especially important as it shows VRAY is winning new customers despite the recent competitive entrance from Elekta. While sales and orders can be difficult to predict on a quarterly basis, we believe this is an early sign that the new CEO’s strategy is working” wrote Lavin. The analyst concluded “since orders are likely most important to investors, we view this as a stellar report.”A similarly bullish perspective comes from Cantor Fitzgerald’s Craig Bijou. The analyst left a recent meeting with management "more bullish on the opportunity ahead” for ViewRay. Despite the rally in shares, he still sees ‘significant upside’ potential thanks to increased revenue and margin expansion.Notably, Bijou argues that management's goal to reduce the time from purchase order to revenue recognition could drive "meaningful upside" to Street numbers in 2020. Overall, five analysts have published buy ratings on VRAY in the last three months with an average price target of $13.40 (50% upside potential). See what other Top Analysts are saying about VRAY. Find your own ‘Strong Buy’ stocksHere we covered top stock picks currently trading for under $10. You can discover more compelling 'Strong Buy' stocks with the Top Analyst Stocks tool. This highlights the most promising stocks based on the latest recommendations from the Street's best-performing analysts. Go to Top Analysts Stocks Tool now.

  • PR Newswire2 months ago

    Sirnaomics Appoints Allan L. Shaw as Chief Financial Officer

    GAITHERSBURG, Md., May 28, 2019 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the appointment of Allan L. Shaw, CPA, as the company's Chief Financial Officer (CFO). Mr. Shaw is a highly regarded biopharmaceutical executive and board member with more than twenty years of financial and strategic leadership experience. "This is a very exciting time for Sirnaomics having recently completed a $47 million financing, reflecting the company's innovation and tremendous potential. I look forward to working with this dedicated and talented team of industry experts to deliver on our shared goal of developing novel therapeutics that address patient care in areas of high unmet medical need," stated Mr. Shaw.

  • Have Insiders Been Buying Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares This Year?
    Simply Wall St.2 months ago

    Have Insiders Been Buying Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • PR Newswire2 months ago

    Syndax to Present at the UBS Global Healthcare Conference

    WALTHAM, Mass. , May 14, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing ...

  • Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks3 months ago

    Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

    Syndax (SNDX) delivered earnings and revenue surprises of 5.36% and -0.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Syndax: 1Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 53 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • PR Newswire3 months ago

    Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update

    - E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 - - IND filing for targeted menin inhibitor SNDX-5613 on track for 2Q19 - - Company ...

  • PR Newswire3 months ago

    Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019

    WALTHAM, Mass., April 29, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2019 financial results on Monday, May 6, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 6, to discuss the Company's financial results and provide a general business update.

  • PR Newswire4 months ago

    Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting

    - 19% objective response rate and 36% clinical benefit rate, with 13-month median duration of response in melanoma patients whose disease progressed on or after anti-PD-1 therapy - - Gene expression analyses ...

  • PR Newswire4 months ago

    Syndax Announces $26.2 Million Offering of Common Stock and Warrants

    WALTHAM, Mass., March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnology Value Fund, L.P. ("BVF") and other leading life sciences investors for the purchase of 4,366,666 shares of common stock at a purchase price of $6.00 per share, representing a premium of 30% to the share price as of market close on Tuesday, March 26, as well as warrants to purchase up to 2,183,331 shares of common stock at an exercise price of $12.00 per share, and warrants to purchase up to 2,183,335 shares of common stock at an exercise price of $18.00 per share.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of SNDX earnings conference call or presentation 7-Mar-19 9:30pm GMT

    Q4 2018 Syndax Pharmaceuticals Inc Earnings Call

  • What Do Analysts Think About Syndax Pharmaceuticals, Inc.’s (NASDAQ:SNDX) Earnings Trend?
    Simply Wall St.4 months ago

    What Do Analysts Think About Syndax Pharmaceuticals, Inc.’s (NASDAQ:SNDX) Earnings Trend?

    Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) latest earnings update in December 2018 showed company earnings became less negative compared to the previous year's level as a result of recent tailwinds Investors mayRead More...

  • PR Newswire5 months ago

    Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update

    - Next interim OS assessment for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 - - IND filing for targeted therapy SNDX-5613, the Company's Menin inhibitor, expected in 2Q19 ...

  • PR Newswire5 months ago

    Syndax to Present at the Cowen 39th Annual Health Care Conference

    WALTHAM, Mass. , March 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing ...

  • PR Newswire5 months ago

    Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019

    WALTHAM, Mass. , Feb. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing ...

  • PR Newswire5 months ago

    Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019

    WALTHAM, Mass. , Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing ...

  • Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
    Zacks5 months ago

    Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

    Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire5 months ago

    New Research: Key Drivers of Growth for Cronos Group, Spectrum Brands, Black Hills, Entercom Communications, CSS Industries, and Syndax Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire6 months ago

    Syndax Highlights 2019 Clinical and Corporate Outlook

    WALTHAM, Mass., Jan. 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today provided a 2019 clinical and corporate outlook. "2019 is slated to be a milestone-rich time for Syndax, with data expected from multiple trials within our ENCORE program of entinostat in combination with checkpoint therapy in platinum resistant ovarian cancer, triple negative breast cancer, and anti-PD-1-pretreated melanoma, all of which we believe represent underserved areas with significant market opportunity," said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax.

  • Can We See Significant Institutional Ownership On The Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Share Register?
    Simply Wall St.7 months ago

    Can We See Significant Institutional Ownership On The Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Share Register?

    The big shareholder groups in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of SNDX earnings conference call or presentation 5-Nov-18 9:30pm GMT

    Q3 2018 Syndax Pharmaceuticals Inc Earnings Call